Traders should monitor the outcome of the April 16 FDA meeting for guidance on trial design and potential approval pathway, which could serve as a near-term catalyst. Positive alignment with the FDA may support valuation upside in this niche oncology space.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 6 $0.9500entry
- T+1 · 7mo ago −5.26%α −5.33% · $0.9000
- T+5 · 7mo ago +10.53%α +6.39% · $1.05
- T+20 · 7mo ago −2.11%α −11.09% · $0.9300
- T+60 · 5mo ago −5.19%α −18.66% · $0.9007
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech announced a scheduled Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in combination with a checkpoint inhibitor for squamous cell anal carcinoma (SCAC). The company plans to propose a single-arm pivotal study enrolling 60–70 patients with objective response rate as the primary endpoint, supported by clinical data showing approximately 30% ORR and 17-month median duration of response.
Key Facts
- Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in SCAC.
- The proposed pivotal study is single-arm, enrolling 60–70 patients, with objective response rate (ORR) as the primary endpoint.
- Clinical data from Cohort 4 of the GOBLET study showed approximately 30% ORR and 17-month median duration of response in late-line SCAC patients.
- SCAC is a rare cancer with limited second-line treatment options, positioning pelareorep for a potentially efficient approval path.
- The FDA has previously granted Fast Track designation to pelareorep for colorectal and pancreatic cancers.
Financial Impact
No immediate financial impact disclosed; potential long-term value hinges on FDA agreement and study initiation.
Risk Factors
- FDA may not agree to the proposed single-arm pivotal study design or endpoint.
- Limited patient population and rare cancer indication may constrain commercial revenue potential despite approval.
- Company remains dependent on future financing or partnerships to fund pivotal development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000024 |
| Document: oncolyticsfdascacmeetingpr.htm | 0001129928-26-000024 |
| Document: 0001129928-26-000024-index-headers.html | 0001129928-26-000024 |
| Document: 0001129928-26-000024-index.html | 0001129928-26-000024 |
| Document: 0001129928-26-000024.txt | 0001129928-26-000024 |
Track record
32 reports on ONCY
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +6.45% at T+20 after the Mar 31, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers